Immersive cardiac training tech gaining ground in high-stakes procedures

Tern plc

Fundamental XR is emerging as a key player in the shift toward immersive clinical training, offering a multimodal platform designed specifically for intracardiac interventions. Instead of relying on flat-screen visuals or isolated device simulations, this system merges real-world imaging modalities, including ultrasound, CT, fluoroscopy and 3D reconstructions, into a single virtual or mixed reality environment.

This matters because traditional training models are struggling to keep up with the demands of structural heart procedures. These interventions are becoming more intricate, with tighter tolerances and rising expectations around safety and efficiency. Platforms like Fundamental XR offer hospitals and manufacturers a tool to accelerate operator readiness, reduce avoidable errors, and improve procedural consistency, all of which are directly relevant to long-term value creation in this space.

What differentiates this model is its integration of full procedural context. Trainees don’t just learn isolated movements — they simulate the entire sequence of an intracardiac case, complete with real-time feedback from multimodal imaging. That creates a more realistic environment to develop the subtle spatial and tactile judgment needed for safe catheter navigation and device deployment. It also shortens the learning curve for new devices, which is increasingly important as manufacturers push for faster adoption cycles.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Pharmaceutical groups move closer to the consumer in strategic marketing reset

Pharmaceutical marketing is shifting towards direct consumer engagement, reshaping how companies compete and manage risk in a digital environment.

Changing clinician behaviour reshapes commercial strategy for 2026

As clinician engagement becomes more digital and measurable, companies that act on behavioural data can improve targeting, reduce risk and strengthen competitive positioning in 2026.

Tern Plc launches £384,408 Open Offer at 0.40p per share

Tern Plc has announced an Open Offer to raise up to £384,408 through the issue of up to 96,101,957 shares at 0.40p each, a 20% discount to the 12 February 2026 closing price.

Search

Search